These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12780752)

  • 1. Hypothalamic growth hormone-releasing hormone (GHRH) cell number is increased in human illness, but is not reduced in Prader-Willi syndrome or obesity.
    Goldstone AP; Unmehopa UA; Swaab DF
    Clin Endocrinol (Oxf); 2003 Jun; 58(6):743-55. PubMed ID: 12780752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome.
    Grugni G; Guzzaloni G; Moro D; Bettio D; De Medici C; Morabito F
    Clin Endocrinol (Oxf); 1998 Jun; 48(6):769-75. PubMed ID: 9713567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.
    Grugni G; Marzullo P; Ragusa L; Sartorio A; Trifirò G; Liuzzi A; Crinò A;
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):492-9. PubMed ID: 16984242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GHRH plus arginine and arginine administration evokes the same ratio of GH isoforms levels in young patients with Prader-Willi syndrome.
    Rigamonti AE; Crinò A; Bocchini S; Convertino A; Bidlingmaier M; Haenelt M; Tamini S; Cella SG; Grugni G; Sartorio A
    Growth Horm IGF Res; 2018 Apr; 39():13-18. PubMed ID: 29217318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader-Willi syndrome after GHRH plus arginine administration.
    Rigamonti AE; Grugni G; Marazzi N; Bini S; Bidlingmaier M; Sartorio A
    Growth Horm IGF Res; 2015 Aug; 25(4):168-73. PubMed ID: 26059749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GHRH + arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences.
    Marostica E; Grugni G; De Nicolao G; Marazzi N; Crinò A; Cappa M; Sartorio A
    Growth Horm IGF Res; 2013 Dec; 23(6):261-6. PubMed ID: 24090687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.
    Corrias A; Bellone J; Beccaria L; Bosio L; Trifirò G; Livieri C; Ragusa L; Salvatoni A; Andreo M; Ciampalini P; Tonini G; Crinò A
    J Endocrinol Invest; 2000 Feb; 23(2):84-9. PubMed ID: 10800760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader-Willi adults and obese controls.
    Grugni G; Marostica E; Crinò A; Marzullo P; De Nicolao G; Sartorio A
    Clin Endocrinol (Oxf); 2013 Aug; 79(2):224-31. PubMed ID: 23301953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.
    Grugni G; Guzzaloni G; Morabito F
    J Endocrinol Invest; 2001 May; 24(5):340-8. PubMed ID: 11407654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulated GH levels during the transition phase in Prader-Willi syndrome.
    Grugni G; Marzullo P; Delvecchio M; Iughetti L; Licenziati MR; Osimani S; Ragusa L; Salvatoni A; Sartorio A; Stagi S; Crinò A;
    J Endocrinol Invest; 2021 Jul; 44(7):1465-1474. PubMed ID: 33095904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The growth hormone response to hexarelin in patients with Prader-Willi syndrome.
    Cappa M; Raguso G; Palmiotto T; Faedda A; Gurreri F; Neri G; Deghenghi R; Loche S
    J Endocrinol Invest; 1998 Sep; 21(8):501-5. PubMed ID: 9801990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothalamic NPY and agouti-related protein are increased in human illness but not in Prader-Willi syndrome and other obese subjects.
    Goldstone AP; Unmehopa UA; Bloom SR; Swaab DF
    J Clin Endocrinol Metab; 2002 Feb; 87(2):927-37. PubMed ID: 11836343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body fat excess and stimulated growth hormone levels in adult patients with Prader-Willi syndrome.
    Grugni G; Crinò A; Bertocco P; Marzullo P
    Am J Med Genet A; 2009 Feb; 149A(4):726-31. PubMed ID: 19267411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome.
    Angulo M; Castro-Magana M; Mazur B; Canas JA; Vitollo PM; Sarrantonio M
    J Pediatr Endocrinol Metab; 1996; 9(3):393-400. PubMed ID: 8887149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome.
    Fronczek R; Lammers GJ; Balesar R; Unmehopa UA; Swaab DF
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5466-70. PubMed ID: 15985489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome.
    Donze SH; Damen L; van Alfen-van der Velden JAEM; Bocca G; Finken MJJ; Hoorweg-Nijman GJG; Jira PE; van Leeuwen M; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):118-123. PubMed ID: 30973645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome.
    Grugni G; Crinò A; Pagani S; Meazza C; Buzi F; De Toni T; Gargantini L; Pilotta A; Pozzan GB; Radetti G; Ragusa L; Salvatoni A; Sartorio A; Bozzola M;
    J Pediatr Endocrinol Metab; 2011; 24(7-8):477-81. PubMed ID: 21932585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of adiponectin receptor expression with cytokines and insulin sensitivity in growth hormone (GH)-treated children with Prader-Willi syndrome and in non-GH-treated obese children.
    Sohn YB; Kwak MJ; Kim SJ; Park SW; Kim CH; Kim MY; Kwon EK; Paik KH; Jin DK
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1371-7. PubMed ID: 20061428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment.
    Hoybye C; Bruun JM; Richelsen B; Flyvbjerg A; Frystyk J
    Eur J Endocrinol; 2004 Oct; 151(4):457-61. PubMed ID: 15476445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF-1 Levels, Complex Formation, and IGF Bioactivity in Growth Hormone-Treated Children With Prader-Willi Syndrome.
    Bakker NE; van Doorn J; Renes JS; Donker GH; Hokken-Koelega AC
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3041-9. PubMed ID: 26050733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.